Synergy Pharmaceuticals — Investor Presentation (January 2010)
36 slides from Synergy Pharmaceuticals's investor presentation, Jan 8, 2010
Slide 1: Developing new treatments for GI Disorders and Diseases
Developing new treatments for GI Disorders and Diseases January 2010 Corporate Presentation
Slide 2: Forward-Looking Information
Certain statements made in this presentation are forward-looking. Such statements are indicated by words such as “expect,” “should,” “anticipate” and similar words indicating uncertainty in facts and figures. Although Synergy believes that the expectations reflected in such forward-looking statement
Slide 3: Introduction to Synergy Pharmaceuticals – Key Points
Introduction to Synergy Pharmaceuticals Synergy Pharmaceuticals – Key Points Technology Proprietary technology, not in-licensed Major implications to treat GI disorders Platform potential Strong IP position Application SP-304 to treat chronic constipation and IBS-C SP-333 to treat IBD Advantages Hum
Slide 4: GI Disorders & Diseases Significant Market Opportunity
GI Disorders & Diseases Significant Market Opportunity
Slide 5: Significant Unmet Medical Need
Significant Unmet Medical Need Hard and lumpy stools, straining during defecation, a sensation of incomplete evacuation, and fewer than three bowel movements per week Significantly affects patients’ quality of life by impairing their ability to work and participate in typical daily activities Limite
Slide 6: The Market for GI-Disorder Drug
The Market for GI-Disorder Drug World: 100 M people with chronic constipation and IBS-C Wide prevalence: Up to 15% and 20% of the population respectively Severe: 20 M people in US, Europe and Japan 7.5 M US 7.5 M Europe 5.0 M Japan $27 Billion total market size More than 1 Million patients More than
Slide 7: Major Game-Changing Event: Novartis Zelnorm withdrawn
Major “Game–Changing” Event: Novartis Zelnorm® (tegaserod) 5-HT4 agonist withdrawn from market in spring 2007 due to cardio-toxicity $560 M sales in 2006, worldwide 32% growth, year on year Approved for chronic constipation and IBS-C Major impact on all future 5-HT4 agonist candidates Highlights nee
Slide 8: Competitive landscape – few approved products to fill Zelnorm absence
Competitive landscape – few approved products to fill Zelnorm absence Amitiza® Amitiza® (lubiprostone) from Sucampo/Takeda Chloride C-2 channel activator Absorbed compound Main side effect is nausea - to 30% of patients Sets high price for market ~$3.80 / day retail ~$3.35 / day ex-factory
Slide 9: GC-C receptor agonists
GC-C receptor agonists
Slide 10: Guanylate Cyclase C Receptors - Physiological mechanism
Guanylate Cyclase C Receptors - Physiological mechanism Guanylate Cyclase C (GC-C) receptors are present on luminal side of gut Key regulator of salt and liquid content of gut The CFTR when activated secretes Cl- and HCO3- into intestinal lumen, along with fluid Side view of the GI tract
Slide 11: Activation of chloride channels increases fluid secretion into GI lumen
Activation of chloride channels increases fluid secretion into GI lumen Amitiza® SP-304 Linaclotide
Slide 12: Big Pharma technology: History of our GC-C receptor agonists
Big Pharma technology: History of our GC-C receptor agonists Technology emanates from cutting edge research on GCC receptors at GD Searle / Monsanto. Key researcher in field: Dr. Kunwar Shailubhai (joined Synergy Pharmaceuticals in 2000) Researchers from Monsanto/Searle eventually joined two biotech
Slide 13: SP-304 lead drug: GC-C Receptor Agonist
SP-304 lead drug: GC-C Receptor Agonist 16-mer analog of uroguanylin Single key amino acid change Locked into stable active conformer Compact stable molecule Thermo and acid stable (100 °C, pH 2) High resistance to proteases Behaves like a small molecule drug More potent than the natural hormone NDD
Slide 14: Two GC-C Receptor Agonists Currently Being Developed
ST-peptide Produced by E. coli bacteria Uroguanylin Natural Hormone Linaclotide ST-peptide Analog NDECELCVNVACTGCL SP-304 Uroguanylin Analog Two GC-C Receptor Agonists Currently Being Developed for Chronic Constipation and IBS NSSNSSNYCCELCCNPACTGCY CCEYCCNPACTGCY NDDCELCVNVACTGCL Colored lines deno
Slide 15: SP-304 Phase I Trial in Volunteers
Conclusions from study No SP-304 systemic absorption observed – all administered doses PK collected through 48 hours post-dose SP-304 showed pharmacodynamic effects indicative of drug effect Phase I Trial in Volunteers Protocol No. SP-SP304101-08 “Single-site, Randomized, Double-blind, Placebo-Contr
Slide 16: Adverse Event (AE) Profile
Adverse Event (AE) Profile The following grade 1 AEs were reported: Diarrhea (20.7%) - defined as increase in # of BM from baseline 81.8% occurred at doses of < 5.4 mg Abdominal Discomfort (5.6%) All 3 occurred at 24.3 mg dose Headache (3.7%) 1 occurred at 0.9 mg and 1 occurred at 24.3 mg dose Nause
Slide 17: Study Summary
Study Summary No systemic absorption of SP-304 observed at all administered doses PK collected through 48 hours post-dose SP-304 was well-tolerated Did not reach an MTD No serious adverse events reported Minimal AEs reported
Slide 18: Next three clinical trials planned for SP-304 in CIC and IBS-C
Next three clinical trials planned for SP-304 in CIC and IBS-C Phase 2a 14-day repeated-dose, placebo-controlled dose escalation trial in CIC patients (N~ 60) Note: linaclotide gave favorable data in 14-day Phase IIa repeated-dose study in CIC Phase 2b 28-day dose-ranging, placebo-controlled trial i
Slide 19: SP-304 Clinical Development Timeline
SP-304 Clinical Development Timeline SP-304 manufacture scale-up underway SP-304 formulation presently underway Initiate Phase 2a 14-day CC trial Initiate Phase 2b 28-day, fixed dose 28-day CC clinical trial Expect clinical data to be available to set doses for 28-day trial IND Amendment filed Janua
Slide 20: Synergy's SP-304 Clinical Strategic Focus
Synergy’s SP-304 Clinical Strategic Focus Focus clinical development of SP-304 to beat linaclotide with lower diarrhea adverse events (AE’s) Mechanistic advantage of SP-304 over linaclotide – pH dependency to binding constant Seek labeling and marketing advantages with SP-304
Slide 21: SP-304 Rationale for 'Best-in-Class'
SP-304 Rationale for ‘Best-in-Class’
Slide 22: Structural Motifs of GC-C Receptor Agonists Currently Being Developed
Structural Motifs of GC-C Receptor Agonists Currently Being Developed Modulates binding constant with mucosal acidity Colored lines denote disulphide bonds Linaclotide ST-peptide Analog NDECELCVNVACTGCL SP-304 Uroguanylin Analog CCEYCCNPACTGCY Defines agonist activity Defines agonist activity
Slide 23: Physiological Role of N Terminus of Uroguanylin
Physiological Role of N Terminus of Uroguanylin Physiological activity of uroguanylin is regulated by mucosal acidity Mucosal acidity provides physiological ‘ON’ and ‘OFF’ switch for binding of uroguanylin to GC-C First three amino acids at N-terminus (NDD) are critical for pH-mediated binding of ur
Slide 24: N-terminal Amino Acids are Critical for pH-mediated Regulation
N-terminal Amino Acids are Critical for pH-mediated Regulation of Physiological Activity Hamra et al., PNAS 1997 NDD at the N-terminus of uroguanylin (UG) - and NDE of SP-304 - are crucial for the physiological ‘ON’ and ‘OFF’ mechanism for binding to GC-C Minus NDD UG Minus NDD UG N D D C E L C V N
Slide 25: Key Intellectual Property
Key Intellectual Property Patent No. US 7,041,786 Date of Patent May 9, 2006 Title Guanylate cyclase receptor agonists for the treatment of tissue inflammation and carcinogenesis Inventors K. Shailubhai, G. Nikiforovich, G. Jacob Assignee Synergy/Callisto Pharmaceuticals, Inc. Related US Appl. Data
Slide 26: Platform Technology SP-333
Platform Technology SP-333
Slide 27: GC-C Receptor Agonist Program is a Technology Platform
Synergy’s GC-C Receptor Agonist Program is a Technology Platform “Second-generation” drug positioned for ulcerative colitis (UC) IND planned for 3Q2010 First trial in healthy volunteers to test for systemic absorption IP status – Key comp-of-matter patent application published in Dec. 2008 SP-333 to
Slide 28: Activation of GC-C receptor leads to GI anti-inflammatory activity
Activation of GC-C receptor leads to GI anti-inflammatory activity cAMP AMP PKA PDE-III GTP PKG-II cGMP Na+ Ca+ Na+ Ca+ Cl- HCO3- HCO3- Cl- ClC2 CFTR CNG GC-C SP-304 SP-333 Anti-proliferative Anti-inflammatory Cl- HCO3- Na+/K+ homeostasis Amitiza® CIC & IBS IBD CANCER Intestinal lumen Epithelial mem
Slide 29: Efficacy of SP-304 in Animal Models of Ulcerative Colitis
Efficacy of SP-304 in Animal Models of Ulcerative Colitis [SP-333 studies in progress] Efficacy of SP-304 has been validated in three different acute animal models of ulcerative colitis TNBS-induced colitis in Balb/c mouse TNBS-induced colitis in BDF1 mouse DSS-induced colitis in BDF1 mouse Prelimin
Slide 30: TNBS Injected Balb/c mice Treated with SP-304
TNBS Injected Balb/c mice Treated with SP-304 show histological improvement and suppressed intestinal secretion of pro-inflammatory cytokines 0 40 80 120 IL-12 p40 IL-23 TNF Cytokines, pg/ml Control SP304, 50 mg/day 160 0 5 10 15 20 25 Histopathology Score SP-304 (mg/day) 0 10 20 50 n-9 n-8 n-4 n-5
Slide 31: Initial clinical trial planned for SP-333
Initial clinical trial planned for SP-333 Phase I single-dose, dose-escalation trial in healthy volunteers (N = 40) Safety, tolerability and PK of orally administered SP-333 Establish that SP-333 is not systemically absorbed in volunteers To be followed by evaluation in ulcerative colitis patients
Slide 32: Summary
Summary
Slide 33: GC-C receptor agonists have an established valuation
GC-C receptor agonists have an established valuation Partnership deal announced between Ironwood and Forest Laboratories for North American rights to linaclotide Forest paid $70 M upfront and $260 M in near term milestones for 50/50 rights to US, plus Canada and Mexico September 2007 May 2009 Almira
Slide 34: Future Synergy Value Creation Milestones
Future Synergy Value Creation Milestones 1Q2010 * Initiate SP-304 Phase 2a 14-day CC trial 4Q2010 * Phase 2a clinical data 2010 * File IND on SP-333 (FIH clinical data – 1Q 2011) 1Q2011 Initiate SP-304 Phase 2b 28-day CC trial 2Q2011 Initiate SP-304 Phase 2b 90-day IBS-C trial * Key 2010 Future Valu
Slide 35: Synergy: Our Opportunity
Synergy: Our Opportunity SP-304 is less than 9 months away from completing Phase IIa proof of efficacy trial in chronic constipation Oral drugs for GI disorders & diseases Targeted therapy – specific selective receptor in GI tract No systemic absorption – low risk of toxicity Clinical proof-of-princ
Slide 36: Synergy Pharmaceuticals – Thank You
Synergy Pharmaceuticals THANK YOU
Synergy Pharmaceuticals — Investor Presentation (January 2010) on 6ix